Literature DB >> 11231286

Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.

M Minakuchi1, N Kakazu, M J Gorrin-Rivas, T Abe, T D Copeland, K Ueda, Y Adachi.   

Abstract

SET, the translocation breakpoint-encoded protein in acute undifferentiated leukemia (AUL), is a 39-kDa nuclear phosphoprotein and has an inhibitory activity for protein phosphatase 2A (PP2A). SET is fused to a putative oncoprotein, CAN/NUP214, in AUL and is thought to play a key role in leukemogenesis by its nuclear localization, protein-protein interactions and PP2A inhibitory activity. Here, we describe the isolation and characterization of a novel cDNA encoding a protein with 1542 amino-acid residues that specifically interacts in a yeast two-hybrid system as well as in human cells with SET. This new protein, which we name SEB (SET-binding protein), is identified as a 170-kDa protein by immunoprecipitation with a specific antibody and is localized predominantly in the nucleus. SEB1238--1434 is determined as a SET-binding region that specifically binds to SET182--223. SEB also has an oncoprotein Ski homologous region (amino acids 654--858), six PEST sequences and three sequential PPLPPPPP repeats at the C-terminus. SEB mRNA is expressed ubiquitously in all human adult tissues and cells examined. The SEB gene locus is assigned to the chromosome 18q21.1 that contains candidate tumor suppressor genes associated with deletions in cancer and leukemia. Although the function of SEB is not known, we propose that SEB plays a key role in the mechanism of SET-related leukemogenesis and tumorigenesis, perhaps by suppressing SET function or by regulating the transforming activity of Ski in the nucleus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231286     DOI: 10.1046/j.1432-1327.2001.02000.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  39 in total

1.  [Unusual facies with delayed development and multiple malformations in a 14-month-old boy].

Authors:  Tong Lu; Yi Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  De novo mutations of SETBP1 cause Schinzel-Giedion syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Christian Gilissen; Peer Arts; Bart van Lier; Marloes Steehouwer; Petra de Vries; Rick de Reuver; Nienke Wieskamp; Geert Mortier; Koen Devriendt; Marta Z Amorim; Nicole Revencu; Alexa Kidd; Mafalda Barbosa; Anne Turner; Janine Smith; Christina Oley; Alex Henderson; Ian M Hayes; Elizabeth M Thompson; Han G Brunner; Bert B A de Vries; Joris A Veltman
Journal:  Nat Genet       Date:  2010-05-02       Impact factor: 38.330

Review 3.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

4.  Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.

Authors:  Hirotoshi Sakaguchi; Yusuke Okuno; Hideki Muramatsu; Kenichi Yoshida; Yuichi Shiraishi; Mariko Takahashi; Ayana Kon; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Hideki Makishima; Xinan Wang; Yinyan Xu; Sayoko Doisaki; Asahito Hama; Koji Nakanishi; Yoshiyuki Takahashi; Nao Yoshida; Jaroslaw P Maciejewski; Satoru Miyano; Seishi Ogawa; Seiji Kojima
Journal:  Nat Genet       Date:  2013-07-07       Impact factor: 38.330

5.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

Review 6.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

7.  Protein phosphatase 2A activity affects histone H3 phosphorylation and transcription in Drosophila melanogaster.

Authors:  Scott J Nowak; Chi-Yun Pai; Victor G Corces
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Variation in Galr1 expression determines susceptibility to exocitotoxin-induced cell death in mice.

Authors:  S Kong; A Lorenzana; Q Deng; T H McNeill; P E Schauwecker
Journal:  Genes Brain Behav       Date:  2008-07       Impact factor: 3.449

9.  Downregulation of SETBP1 promoted non-small cell lung cancer progression by inducing cellular EMT and disordered immune status.

Authors:  Hao-Ran Li; Jian Gao; Chun Jin; Jia-Hao Jiang; Jian-Yong Ding
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

10.  Distinct neurological features in a patient with Schinzel-Giedion syndrome caused by a recurrent SETBP1 mutation.

Authors:  Jung Min Ko; Byung Chan Lim; Ki Joong Kim; Yong Seung Hwang; Hye Won Ryu; Jung Ho Lee; Jon Su Kim; Jong-Hee Chae
Journal:  Childs Nerv Syst       Date:  2013-02-12       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.